Dr. Rachel Parker -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Rachel Parker, a Hepatology physician based in Detroit, MI. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Rachel Parker has received $97,413.18 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Rachel Parker
- Medical Specialty: Hepatology
- Practice Location: Detroit, MI, Michigan
- NPI Number: 1267078124
- Transparency Score: 75/100
- Payment Records Span: 2026-03-03 to 2026-03-03
Payment Summary
Dr. Rachel Parker has received a total of $97,413.18 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $97,413.18 per transaction.
- Total Payments Received: $97,413.18
- Number of Transactions: 1
- Average Payment: $97,413.18
- Transparency Score: 75/100 -- This score reflects the overall payment profile relative to peers in Hepatology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Rachel Parker's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Research Funding | $97,413.18 | Clinical trial funding, research grants, and study-related payments |
The largest payment category for Dr. Rachel Parker is Research Funding, accounting for 100% ($97,413.18) of total pharmaceutical payments received. This suggests active involvement in clinical trials and pharmaceutical research programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Rachel Parker. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| Bristol-Myers Squibb | $97,413.18 | 1 |
Dr. Rachel Parker has a financial relationship with Bristol-Myers Squibb, receiving $97,413.18 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Rachel Parker. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Farxiga -- Referenced in payment records from pharmaceutical companies to Dr. Rachel Parker
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Rachel Parker's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Rachel Parker has received $97.4K across 1 pharmaceutical payments as a Hepatology physician in Detroit, MI. Top paying companies include Bristol-Myers Squibb ($97.4K). Dr. Parker received a single, substantial payment of $97,413 in 2026, exclusively for research purposes. This entire payment originated from Bristol-Myers Squibb, indicating a strong relationship with this single pharmaceutical company. The payment is linked to the drug 'Farxiga', suggesting research related to this specific medication.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Rachel Parker is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
When consulting with Dr. Parker, consider asking about the nature of the research funded by Bristol-Myers Squibb and its potential impact on treatment recommendations for conditions related to Farxiga. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Rachel Parker Compares to Other Hepatology Physicians
As a Hepatology specialist, Dr. Parker's payment profile is highly concentrated, unlike many peers who may receive multiple smaller payments across various companies and research areas.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Rachel Parker in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | $97,413.18 | research | Farxiga | 2026-03-03 | Not Assessed |
Frequently Asked Questions About Dr. Rachel Parker's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Rachel Parker received?
Rachel Parker has received a total of $97.4K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Rachel Parker taking too much pharma money?
Rachel Parker has received $97.4K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Hepatology), the types of payments, and how they compare to peers. The largest payment category is research ($97.4K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Rachel Parker?
The top pharmaceutical companies paying Rachel Parker are: Bristol-Myers Squibb ($97.4K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Rachel Parker receive?
Rachel Parker's payments by type: research: $97.4K. Research payments indicate involvement in clinical studies.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Rachel Parker's payments compare to other Hepatology doctors?
To compare, look at the total amount ($97.4K), number of payments (1), and the types of payments received. Hepatology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Rachel Parker's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1267078124). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Rachel Parker's pharma payment profile?
The payment is entirely concentrated with one company (Bristol-Myers Squibb) and one payment type (research). Rachel Parker has received $97.4K in total pharma payments.
How does Rachel Parker compare to peers in Hepatology?
As a Hepatology specialist, Dr. Parker's payment profile is highly concentrated, unlike many peers who may receive multiple smaller payments across various companies and research areas.
Are Rachel Parker's pharma relationships typical for Hepatology?
The single payment represents 100% of the total disclosed amount, highlighting a lack of diversified payment sources.
What should patients of Rachel Parker know about these payments?
When consulting with Dr. Parker, consider asking about the nature of the research funded by Bristol-Myers Squibb and its potential impact on treatment recommendations for conditions related to Farxiga.
What patterns are visible in Rachel Parker's payment history?
The data reflects a future payment (2026), which might be subject to change or cancellation.
Understanding This Doctor Payment Report
This transparency report for Dr. Rachel Parker is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Hepatology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Rachel Parker's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Rachel Parker and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Hepatology Specialty Payment Data -- See payment patterns for all hepatology physicians
- Michigan Physician Payments -- Browse pharmaceutical payments to physicians in Michigan
- Hepatology Physicians in Michigan -- Compare Dr. Rachel Parker to peers in the same state and specialty
- Bristol-Myers Squibb Payment Profile -- View all payments made by Dr. Rachel Parker's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Rachel Parker's NPI (1267078124) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.